-
Something wrong with this record ?
IL-2/JES6-1 mAb complexes dramatically increase sensitivity to LPS through IFN-γ production by CD25+Foxp3- T cells
J. Tomala, P. Weberova, B. Tomalova, Z. Jiraskova Zakostelska, L. Sivak, J. Kovarova, M. Kovar
Language English Country Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Directory of Open Access Journals
from 2013
Free Medical Journals
from 2012
PubMed Central
from 2012
Europe PubMed Central
from 2012
ProQuest Central
from 2012-01-01
Open Access Digital Library
from 2012-01-01
Open Access Digital Library
from 2013-01-01
Health & Medicine (ProQuest)
from 2012-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2012
PubMed
34932467
DOI
10.7554/elife.62432
Knihovny.cz E-resources
- MeSH
- Interferon-gamma deficiency MeSH
- Interleukin-2 metabolism MeSH
- Lipopolysaccharides metabolism MeSH
- Mice, Inbred BALB C MeSH
- Mice, Inbred C57BL MeSH
- Mice, Nude MeSH
- Mice MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Mice MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Complexes of IL-2 and JES6-1 mAb (IL-2/JES6) provide strong sustained IL-2 signal selective for CD25+ cells and thus they potently expand Treg cells. IL-2/JES6 are effective in the treatment of autoimmune diseases and in protecting against rejection of pancreatic islet allografts. However, we found that IL-2/JES6 also dramatically increase sensitivity to LPS-mediated shock in C57BL/6 mice. We demonstrate here that this phenomenon is dependent on endogenous IFN-γ and T cells, as it is not manifested in IFN-γ deficient and nude mice, respectively. Administration of IL-2/JES6 leads to the emergence of CD25+Foxp3-CD4+ and CD25+Foxp3-CD8+ T cells producing IFN-γ in various organs, particularly in the liver. IL-2/JES6 also increase counts of CD11b+CD14+ cells in the blood and the spleen with higher sensitivity to LPS in terms of TNF-α production and induce expression of CD25 in these cells. These findings indicate safety issue for potential use of IL-2/JES6 or similar IL-2-like immunotherapeutics.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22011663
- 003
- CZ-PrNML
- 005
- 20220506131328.0
- 007
- ta
- 008
- 220425s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.7554/eLife.62432 $2 doi
- 035 __
- $a (PubMed)34932467
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Tomala, Jakub $u Laboratory of Tumor Immunology, Institute of Microbiology, Czech Academy of Sciences, Prague, Czech Republic $1 https://orcid.org/0000000263152832
- 245 10
- $a IL-2/JES6-1 mAb complexes dramatically increase sensitivity to LPS through IFN-γ production by CD25+Foxp3- T cells / $c J. Tomala, P. Weberova, B. Tomalova, Z. Jiraskova Zakostelska, L. Sivak, J. Kovarova, M. Kovar
- 520 9_
- $a Complexes of IL-2 and JES6-1 mAb (IL-2/JES6) provide strong sustained IL-2 signal selective for CD25+ cells and thus they potently expand Treg cells. IL-2/JES6 are effective in the treatment of autoimmune diseases and in protecting against rejection of pancreatic islet allografts. However, we found that IL-2/JES6 also dramatically increase sensitivity to LPS-mediated shock in C57BL/6 mice. We demonstrate here that this phenomenon is dependent on endogenous IFN-γ and T cells, as it is not manifested in IFN-γ deficient and nude mice, respectively. Administration of IL-2/JES6 leads to the emergence of CD25+Foxp3-CD4+ and CD25+Foxp3-CD8+ T cells producing IFN-γ in various organs, particularly in the liver. IL-2/JES6 also increase counts of CD11b+CD14+ cells in the blood and the spleen with higher sensitivity to LPS in terms of TNF-α production and induce expression of CD25 in these cells. These findings indicate safety issue for potential use of IL-2/JES6 or similar IL-2-like immunotherapeutics.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a interferon gama $x nedostatek $7 D007371
- 650 _2
- $a interleukin-2 $x metabolismus $7 D007376
- 650 _2
- $a lipopolysacharidy $x metabolismus $7 D008070
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši inbrední BALB C $7 D008807
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a myši nahé $7 D008819
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Weberova, Petra $u Laboratory of Tumor Immunology, Institute of Microbiology, Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Tomalova, Barbora $u Laboratory of Tumor Immunology, Institute of Microbiology, Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Jiraskova Zakostelska, Zuzana $u Laboratory of Cellular and Molecular Immunology, Institute of Microbiology, Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Sivak, Ladislav $u Laboratory of Tumor Immunology, Institute of Microbiology, Czech Academy of Sciences, Prague, Czech Republic $1 https://orcid.org/0000000326238458
- 700 1_
- $a Kovarova, Jirina $u Laboratory of Tumor Immunology, Institute of Microbiology, Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Kovar, Marek $u Laboratory of Tumor Immunology, Institute of Microbiology, Czech Academy of Sciences, Prague, Czech Republic $1 https://orcid.org/0000000266021678
- 773 0_
- $w MED00188753 $t eLife $x 2050-084X $g Roč. 10, č. - (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34932467 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506131320 $b ABA008
- 999 __
- $a ok $b bmc $g 1789326 $s 1162861
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 10 $c - $e 20211221 $i 2050-084X $m eLife $n eLife $x MED00188753
- LZP __
- $a Pubmed-20220425